MS Drugmaker Fined €462.6 Million for Disparaging Rival 🔗 Access full article via Medscape NeurologyThe European Commission fined Teva for abusing its dominant position to delay competition for its multiple sclerosis drug Copaxone. Medscape Medical News Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
